Phil Greenberg is Professor of Medicine & of Immunology at the University of Washington, and Head of the Program in Immunology at the Fred Hutchinson Cancer Research Center. His research has focused on: elucidating fundamental principles of T cell and tumor interactions, developing cellular and molecular approaches to manipulate T cell immunity, and translating insights from the lab to the treatment of cancer patients with an emphasis on adoptive therapy with genetically engineered T cells. He has received multiple professional awards, including the Coley Award from the Cancer Research Institute (CRI), the Team Science Award and the Smalley Award from the Society for the Immunotherapy of Cancer (SITC), and the E. Donnall Thomas Award from the American Society of Hematology (ASH). He has been elected a Fellow of the American Society of Clinical Investigation (ASCI), Fellow of the Association of American Physicians (AAP), Fellow of the American Association for the Advancement of Science (AAAS), Fellow of the Academy of the American Association for Cancer Research (AACR), a Distinguished Fellow of the American Association of Immunologists (AAI), and a Fellow of the Academy of Immuno-Oncology (SITC). He is on the scientific advisory boards of several comprehensive cancer centers and biotech companies, and is a scientific founder of Juno Therapeutics and of Affini-T Therapeutics. Phil served as an elected member of the Board of Directors of the American Association for Cancer Research (AACR), and currently is an Editor-In-Chief of the journal Cancer Immunology Research.